John Rice

发表

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

Hiroshi Yasui, Ken Huang, N. Raje, 2009, Blood.

Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90.

Briana Foley, Laura G. Dubois, Philip F. Hughes, 2010, Chemistry & biology.

Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours.

D. Nowotnik, John Rice, G. Russell-Jones, 2004, Journal of inorganic biochemistry.